Johnson & Johnson (JNJ) will release its FQ2’18 earnings report tomorrow, July 17th, before the market opens. Estimize consensus projects an EPS of $2.08, a 14% YoY growth and 2 cents higher than Wall Street’s prediction. Estimize has been more accurate than Wall Street in JNJ EPS predictions 96% of the time. We anticipate a revenue of $20.326B, an 8% growth (YoY), while Wall Street predicts a revenue of $20.245B.

Johnson & Johnson has been hit by a wave of lawsuits due to its perceived contribution to the opioid epidemic. In April, Kentucky sued the company for its deceptive advertisements stating the painkillers were “rarely addictive”, and many similar suits are still in development. On Thursday, July 12th, 22 women were awarded $4.69B after stating that their ovarian cancer was caused by Johnson & Johnson’s talcum powder. This will not be the last cancer-related lawsuit against the pharmaceutical company; thousands of cases are making their way through court systems.

How do you expect JNJ to perform during this turbulent time?
Photo credit: Austin Kirk